Antimicrobial susceptibility testing (AST) is carried out to determine the possible efficacy of various antibiotics on bacteria, if bacteria have evolved resistance to specific antibiotics, and for antifungal and antiviral species. According to BlueQuark the Global Antimicrobial Susceptibility Testing Market is expected to grow considerably during the forecasted period. Factors such as the surging prevalence of infectious diseases such as pneumonia and bloodstream infections due to a lack of proper sanitization and an unhygienic diet are expected to drive the Antimicrobial Susceptibility market in the forecasted period. Further, the rising prevalence of hospital-acquired infections (HAIs), the patient population base, and increased government awareness to combat antimicrobial resistance are expected to drive the Antimicrobial Susceptibility market in the forecasted period. Furthermore, the increased use of antimicrobial susceptibility testing by biotechnological, pharmaceutical, and biopharmaceutical companies to develop novel & effective therapeutic options is expected to drive the Antimicrobial Susceptibility market in the forecasted period. However, challenges such as the high cost of technologically advanced products and automated instruments, time gaps in determining clinical breakpoints, approval processes for novel antimicrobial drugs, and the complexity of product approval procedures may impede market growth in the forecasted period.

The elevating prevalence of infectious diseases is one of the key factors fueling the growth of the global antimicrobial susceptibility testing market. Contagious diseases such as tuberculosis, malaria, and hepatitis are caused by pathogens like viruses and parasites. The growing incidence of infectious diseases brought on by bacteria and fungi is one of the main drivers of the antimicrobial susceptibility tests market's expansion. Antimicrobial susceptibility tests are utilized to examine susceptibility to administer adequate antimicrobial treatment to patients without side effects. Additionally, assays for antimicrobial susceptibility are available for several testing techniques, including antibacterial, antifungal, and other susceptible testing methods. Antimicrobial susceptibility testing is widely used in clinical diagnosis, medication development, and other therapeutic applications. These are a few of the major propelling forces behind the market for antimicrobial susceptibility tests.

Moreover, recent outbreaks, including Ebola, Zika, dengue, Middle East Respiratory Syndrome (MERS), influenza, and Severe Acute Respiratory Syndrome (SARS), as well as the threat of rising antibiotic resistance (AR), have further increased the concerns on global health. In addition, the rapidly growing population, lifestyle changes, urbanization, civil wars, and climate change have increased the prevalence of infectious diseases. As a result, there has been an increase in products used for diagnosing them. As infectious diseases pose a global threat to healthcare, the demand for their diagnosis with the help of AST is likely to increase steadily, thereby driving the market in the forecasted period. The need for antimicrobial susceptibility testing has been on the rise due to the extending prevalence of infectious disease epidemics like Neisseria meningitides, Neisseria gonorrhoeae, Shigella, and Salmonella serotype Typhi mainly due to lack of water supply, lack of sanitation and unhygienic conditions are also boosting demand for antimicrobial susceptibility testing kits. As a result, medical practitioners have realized the need to perform antibiotic susceptibility tests (ASTs), and they are now a required component of clinical microbiology laboratories. They are anticipated to drive the Antimicrobial Susceptibility Testing market.

North America is expected to dominate the overall antimicrobial susceptibility testing market. This is due to factors such as the rising incidence of antibiotic-resistant infections and increased use of antibiotics in the study region. Antibiotic testing is executed in hospitals to a large range with the latest technologies available. Therefore, hospitals are expected to dominate the market. Antibiotic susceptibility testing helps in the assessment of hospital-based treatment services. The demand for antibiotic susceptibility testing kits is increasing due to the recent shift toward individualized treatments. The share of this segment is mainly accredited to the presence of a well-equipped facility and qualified professionals, the surge in hospital-acquired infectious diseases, and critical companies' initiatives to sell antibiotic susceptibility testing products through hospitals. Antibiograms can be defined as a cumulative result of the AST of a specific microorganism to several antimicrobial drugs. Medical facilities must maintain annual antibiograms for the antimicrobial stewardship programs (ASP), and reports are updated per the resistance trends. Selecting a specific patient population, such as inpatient vs. outpatient, hospital units, such as ICU vs. non-ICU, and infection sites, such as blood, urine, and sputum, provide valuable insights into resistance trends. The antibiogram helps track local antibiotic resistance trends, improving the ability to avoid suboptimal therapies and providing better patient care. Antiblograms are used as a tool for developing guidelines for empiric therapy, making formulary decisions, and monitoring resistance rates over time. Also, the Clinical and Laboratory Standards Institute (CLSI) has formed a consensus guideline to standardize the methods used to construct antibiograms. Although the construction of antibiograms is complex, expensive, and time-consuming, in the era of increasing antibiotic resistance, the demand for antibiograms will grow rapidly, thereby contributing to the development of the global antimicrobial susceptibility testing market in the forecasted period.

The market key players are Biomerieux, Bio-Rad Laboratories, Inc., HiMedia Laboratories, Alifax, and Becton Dickinson, among others.

In January 2023, bioMérieux unveiled its latest automated instrument called MAESTRIA. This innovative instrument is designed to streamline and automate various laboratory processes, offering enhanced efficiency and accuracy in diagnostics and testing procedures.

In May 2022, Qualigen Therapeutics announced that NanoSynex Ltd, a company of Qualigen, recently entered into definitive agreements to acquire a majority stake, featured at BioMed Israel. Innovative Technology by NanoSynex focuses on accelerating antimicrobial susceptibility test results times by six-fold.

Global Antimicrobial Susceptibility Testing Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Antimicrobial Susceptibility Testing Market by segmenting based on Product Type (Manual Products, Automated Products and Consumables), By Method Type (ETEST, Disks Diffusion, Rapid Automation Method and others), and End-User Industry (Hospitals and diagnostic Laboratories, Pharmaceutical & Biotechnology Companies and Others), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.